Micafungin In Sodium Chloride 0.9% is a drug owned by Baxter Healthcare Corp. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 15, 2037. Details of Micafungin In Sodium Chloride 0.9%'s patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12403173 | NA |
Dec, 2037
(12 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Micafungin In Sodium Chloride 0.9% is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Micafungin In Sodium Chloride 0.9%'s family patents as well as insights into ongoing legal events on those patents.
Micafungin In Sodium Chloride 0.9%'s Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Micafungin In Sodium Chloride 0.9%'s generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 15, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Micafungin In Sodium Chloride 0.9% Generic API suppliers:
Micafungin Sodium is the generic name for the brand Micafungin In Sodium Chloride 0.9%. 9 different companies have already filed for the generic of Micafungin In Sodium Chloride 0.9%, with Apotex having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Micafungin In Sodium Chloride 0.9%'s generic
Alternative Brands for Micafungin In Sodium Chloride 0.9%
There are several other brand drugs using the same active ingredient (Micafungin Sodium) as Micafungin In Sodium Chloride 0.9%. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Astellas |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Micafungin Sodium, Micafungin In Sodium Chloride 0.9%'s active ingredient. Check the complete list of approved generic manufacturers for Micafungin In Sodium Chloride 0.9%
About Micafungin In Sodium Chloride 0.9%
Micafungin In Sodium Chloride 0.9% is a drug owned by Baxter Healthcare Corp. Micafungin In Sodium Chloride 0.9% uses Micafungin Sodium as an active ingredient. Micafungin In Sodium Chloride 0.9% was launched by Baxter Hlthcare Corp in 2023.
Approval Date:
Micafungin In Sodium Chloride 0.9% was approved by FDA for market use on 29 September, 2023.
Active Ingredient:
Micafungin In Sodium Chloride 0.9% uses Micafungin Sodium as the active ingredient. Check out other Drugs and Companies using Micafungin Sodium ingredient
Dosage:
Micafungin In Sodium Chloride 0.9% is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 150MG BASE/150ML (EQ 1MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 100MG BASE/100ML (EQ 1MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 50MG BASE/50ML (EQ 1MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |